ClinConnect ClinConnect Logo
Search / Trial NCT05675410

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Launched by NATIONAL CANCER INSTITUTE (NCI) · Jan 6, 2023

Trial Information

Current as of June 27, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying whether adding two specific drugs, brentuximab vedotin and nivolumab, to the standard treatment for early-stage Hodgkin lymphoma can help patients live longer and experience fewer side effects. Standard treatment usually involves chemotherapy, and in some cases, radiation therapy. Brentuximab vedotin is a targeted therapy that attaches to cancer cells and delivers a drug to kill them, while nivolumab helps the immune system recognize and attack the cancer. The trial aims to see if combining these therapies is more effective than the standard treatment alone.

To participate in this trial, patients must be between 5 and 60 years old and have recently been diagnosed with classical Hodgkin lymphoma at stage I or II. They should have measurable cancer that can be seen on imaging tests. Participants can expect to receive either the standard treatment or the combination of standard treatment with the two study drugs, and their health will be closely monitored throughout the trial. It's important for potential participants to discuss their eligibility with their healthcare team and understand that all necessary approvals and consent will be required before joining the study.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients must be 5 to 60 years of age at the time of enrollment
  • Patients with newly diagnosed untreated histologically confirmed classic Hodgkin lymphoma (cHL) (nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted, or not otherwise specified \[NOS\]) with stage I or II disease
  • Patients must have bidimensionally measurable disease (at least one lesion with longest diameter \>= 1.5 cm)
  • Patients must have a whole body or limited whole body PET scan performed within 42 days prior to enrollment. PET-CT is strongly preferred. PET-MRI allowed if intravenous contrast enhanced CT is also obtained
  • Pediatric patients (age 5-17 years) with known or suspected mediastinal disease must have an upright posteroanterior (PA) chest X-ray (CXR) for assessment of bulky mediastinal disease.
  • Note: Pediatric patients who have received both a CT chest and upright PA CXR may meet the definition of bulk through either modality.
  • Patients \>= 18 years must have a performance status corresponding to Zubrod scores of 0, 1 or 2
  • Patients =\< 17 years of age must have a Lansky performance score of \>= 50
  • * Pediatric patients (age 5-17 years): A serum creatinine based on age/gender as follows (within 28 days prior to enrollment):
  • 2 to \< 6 years (age): 0.8 mg/dL (male), 0.8 mg/dL (female)
  • 6 to \< 10 years (age): 1 mg/dL (male), 1 mg/dL (female)
  • 10 to \< 13 years (age): 1.2 mg/dL (male), 1.2 mg/dL (female)
  • 13 to \< 16 years (age): 1.5 mg/dL (male), 1.4 mg/dL (female)
  • \>= 16 years (age): 1.7 mg/dL (male), 1.4 mg/dL (female) OR a 24 hour urine creatinine clearance \>= 50 mL/min/1.73 m\^2 (within 28 days prior to enrollment) OR a glomerular filtration rate (GFR) \>= 50 mL/min/1.73 m\^2 (within 28 days prior to enrollment). GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard)
  • Note: Estimated GFR (eGFR) from serum or plasma creatinine, cystatin C or other estimates are not acceptable for determining eligibility
  • For adult patients (age 18 years or older) (within 28 days prior to enrollment): Creatinine clearance \>= 30 mL/min, as estimated by the Cockcroft and Gault formula or a 24-hour urine collection. The creatinine value used in the calculation must have been obtained within 28 days prior to registration. Estimated creatinine clearance is based on actual body weight
  • Total bilirubin =\< 2 x upper limit of normal (ULN) (within 28 days prior to enrollment)
  • Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome
  • Aspartate aminotransferase (AST) =\< 3 x ULN (within 28 days prior to enrollment)
  • Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome
  • Alanine aminotransferase (ALT) =\< 3 x ULN (within 28 days prior to enrollment)
  • Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome
  • Shortening fraction of \>= 27% by echocardiogram (ECHO), multigated acquisition scan (MUGA), or functional cardiac imaging scan (within 28 days prior to enrollment) or ejection fraction of \>= 50% by radionuclide angiogram, ECHO, MUGA, or cardiac imaging scan (within 28 days prior to enrollment)
  • Diffusion capacity of the lung for carbon monoxide (DLCO) \>= 50% of predicted value as corrected for hemoglobin by pulmonary function test (PFT) (within 28 days prior to enrollment). If unable to obtain PFTs, the criterion is: a pulse oximetry reading of \> 92% on room air
  • Known human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Exclusion Criteria:
  • Patients with nodular lymphocyte predominant Hodgkin lymphoma
  • Patients with a history of active interstitial pneumonitis or interstitial lung disease
  • Patients with a diagnosis of inherited or acquired immunodeficiency that is poorly controlled or requiring active medications, such as primary immunodeficiency syndromes or organ transplant recipients
  • Patients with any known uncontrolled intercurrent illness that would jeopardize the patient's safety such as infection, autoimmune conditions, cardiac arrhythmias, angina pectoris, and gastrointestinal disorders affecting swallowing and/or absorption of pills
  • Patients with a condition requiring systemic treatment with either corticosteroids (defined as equivalent to \> 10 mg daily predniSONE for patients \>= 18 years or \> 0.5 mg/kg \[up to 10 mg/day\] for patients \< 18 years) or other immunosuppressive medications within 14 days prior to enrollment
  • Note: Replacement therapy such as thyroxine, insulin, or physiologic corticosteroid for adrenal or pituitary insufficiency is not considered a form of systemic treatment. Inhaled or topical steroids, and adrenal replacement doses (=\< 10 mg daily for patients \>= 18 years or =\< 0.5 mg/kg \[up to 10 mg/day\] predniSONE equivalents) are permitted in the absence of active autoimmune disease
  • Note: Steroid use for the control of Hodgkin lymphoma symptoms is allowable, but must be discontinued by cycle 1, day 1
  • Short term use of corticosteroids for premedication or treatment of an allergy or hypersensitivity is considered an acceptable use of corticosteroids.
  • Patients with peripheral neuropathy \> grade 1 at the time of enrollment or patients with known Charcot-Marie-Tooth syndrome
  • Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen
  • Administration of prior chemotherapy, radiation, or antibody-based treatment for cHL
  • Prior solid organ transplant
  • Prior allogeneic stem cell transplantation
  • Live vaccine within 30 days prior to planned day 1 of protocol therapy (e.g., measles, mumps, rubella, varicella, yellow fever, rabies, bacillus Calmette Guerin \[BCG\], oral polio vaccine, and oral typhoid). Administration of messenger ribonucleic acid (mRNA) vaccines are permitted
  • Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test within 28 days prior to enrollment is required for female patients of childbearing potential
  • Lactating females who plan to breastfeed their infants starting with the first dose of study therapy and for at least 6 months after the last treatment
  • Sexually active patients of reproductive potential who have not agreed to use a highly effective contraceptive method for the duration of their study drug therapy. Following therapy, patients will be advised to use contraception as per institutional practice or as listed below for investigational agents, whichever is longer
  • Men and women of childbearing potential must continue contraception for a period of 6 months after last dose of brentuximab vedotin
  • Women of child-bearing potential (WOCBP) must continue contraception for a period of at least 5 months after the last dose of nivolumab
  • All patients and/or their parents or legal guardians must sign a written informed consent
  • All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

About National Cancer Institute (Nci)

The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.

Locations

Chicago, Illinois, United States

Durham, North Carolina, United States

Charleston, South Carolina, United States

Cleveland, Ohio, United States

Philadelphia, Pennsylvania, United States

Buffalo, New York, United States

Saint Louis, Missouri, United States

Detroit, Michigan, United States

Providence, Rhode Island, United States

Dallas, Texas, United States

Ottawa, Ontario, Canada

Kalamazoo, Michigan, United States

Edina, Minnesota, United States

Maywood, Illinois, United States

Loma Linda, California, United States

Detroit, Michigan, United States

Newark, New Jersey, United States

Toms River, New Jersey, United States

Bangor, Maine, United States

Winnipeg, Manitoba, Canada

Anchorage, Alaska, United States

Hackensack, New Jersey, United States

Edmonton, Alberta, Canada

Peoria, Illinois, United States

Wichita, Kansas, United States

Oklahoma City, Oklahoma, United States

Temple, Texas, United States

Toronto, Ontario, Canada

Duarte, California, United States

Des Moines, Iowa, United States

Orange, California, United States

Scarborough, Maine, United States

Akron, Ohio, United States

Lubbock, Texas, United States

Norfolk, Virginia, United States

La Crosse, Wisconsin, United States

New York, New York, United States

Long Branch, New Jersey, United States

Baltimore, Maryland, United States

Little Rock, Arkansas, United States

Saint Paul, Minnesota, United States

Des Moines, Iowa, United States

Portsmouth, Virginia, United States

Halifax, Nova Scotia, Canada

Kalamazoo, Michigan, United States

Traverse City, Michigan, United States

Jackson, Mississippi, United States

Minneapolis, Minnesota, United States

New Brunswick, New Jersey, United States

Austin, Texas, United States

Corpus Christi, Texas, United States

Hamilton, Ontario, Canada

Quebec, , Canada

Hershey, Pennsylvania, United States

Charlottesville, Virginia, United States

Houston, Texas, United States

Coon Rapids, Minnesota, United States

Renton, Washington, United States

Urbana, Illinois, United States

Minneapolis, Minnesota, United States

Chesterfield, Missouri, United States

Effingham, Illinois, United States

San Antonio, Texas, United States

Springfield, Illinois, United States

Downers Grove, Illinois, United States

Portland, Oregon, United States

Hazel Crest, Illinois, United States

Cincinnati, Ohio, United States

Troy, Michigan, United States

San Antonio, Texas, United States

Boston, Massachusetts, United States

Los Angeles, California, United States

Rochester, New York, United States

Danville, Pennsylvania, United States

Salt Lake City, Utah, United States

Orange, California, United States

Washington, District Of Columbia, United States

Orlando, Florida, United States

Atlanta, Georgia, United States

Chicago, Illinois, United States

Chicago, Illinois, United States

Iowa City, Iowa, United States

New Orleans, Louisiana, United States

Baltimore, Maryland, United States

Baltimore, Maryland, United States

Detroit, Michigan, United States

Minneapolis, Minnesota, United States

Omaha, Nebraska, United States

New Brunswick, New Jersey, United States

New York, New York, United States

New York, New York, United States

New York, New York, United States

Syracuse, New York, United States

Chapel Hill, North Carolina, United States

Winston Salem, North Carolina, United States

Fargo, North Dakota, United States

Nashville, Tennessee, United States

Burlington, Vermont, United States

Hartford, Connecticut, United States

Aurora, Illinois, United States

Lexington, Kentucky, United States

Camden, New Jersey, United States

Neptune, New Jersey, United States

Charlotte, North Carolina, United States

Allentown, Pennsylvania, United States

Falls Church, Virginia, United States

Washington, District Of Columbia, United States

Honolulu, Hawaii, United States

Elmhurst, Illinois, United States

Saint Louis Park, Minnesota, United States

Livingston, New Jersey, United States

Portland, Oregon, United States

Glens Falls, New York, United States

Louisville, Kentucky, United States

Milwaukee, Wisconsin, United States

Grand Rapids, Michigan, United States

Portland, Oregon, United States

Oak Lawn, Illinois, United States

Cleveland, Ohio, United States

Phoenix, Arizona, United States

Oakland, California, United States

San Diego, California, United States

Aurora, Colorado, United States

Wilmington, Delaware, United States

Fort Lauderdale, Florida, United States

Hollywood, Florida, United States

Jacksonville, Florida, United States

Miami, Florida, United States

Tampa, Florida, United States

West Palm Beach, Florida, United States

Chicago, Illinois, United States

Park Ridge, Illinois, United States

New Orleans, Louisiana, United States

Ann Arbor, Michigan, United States

East Lansing, Michigan, United States

Royal Oak, Michigan, United States

Saint Louis, Missouri, United States

New Brunswick, New Jersey, United States

Paterson, New Jersey, United States

Albuquerque, New Mexico, United States

Albany, New York, United States

New Hyde Park, New York, United States

Stony Brook, New York, United States

Columbus, Ohio, United States

Dayton, Ohio, United States

Philadelphia, Pennsylvania, United States

Pittsburgh, Pennsylvania, United States

Sioux Falls, South Dakota, United States

Chattanooga, Tennessee, United States

Knoxville, Tennessee, United States

Dallas, Texas, United States

Fort Worth, Texas, United States

Houston, Texas, United States

Salt Lake City, Utah, United States

Richmond, Virginia, United States

Seattle, Washington, United States

Spokane, Washington, United States

Tacoma, Washington, United States

Montreal, Quebec, Canada

Downey, California, United States

Long Beach, California, United States

Fort Myers, Florida, United States

Gainesville, Florida, United States

Orlando, Florida, United States

Orlando, Florida, United States

Saint Petersburg, Florida, United States

Atlanta, Georgia, United States

Augusta, Georgia, United States

Oak Lawn, Illinois, United States

Indianapolis, Indiana, United States

Louisville, Kentucky, United States

Rochester, Minnesota, United States

Kansas City, Missouri, United States

Saint Louis, Missouri, United States

Omaha, Nebraska, United States

Las Vegas, Nevada, United States

Morristown, New Jersey, United States

Bronx, New York, United States

Mineola, New York, United States

Asheville, North Carolina, United States

Toledo, Ohio, United States

Columbia, South Carolina, United States

Greenville, South Carolina, United States

Roanoke, Virginia, United States

Green Bay, Wisconsin, United States

Madison, Wisconsin, United States

Marshfield, Wisconsin, United States

Milwaukee, Wisconsin, United States

London, Ontario, Canada

Montreal, Quebec, Canada

Portland, Oregon, United States

Decatur, Illinois, United States

Tampa, Florida, United States

Chicago, Illinois, United States

New Haven, Connecticut, United States

Los Angeles, California, United States

Reed City, Michigan, United States

Fremont, California, United States

Sacramento, California, United States

San Francisco, California, United States

San Jose, California, United States

San Leandro, California, United States

Santa Rosa, California, United States

South San Francisco, California, United States

Vallejo, California, United States

Walnut Creek, California, United States

Hartford, Connecticut, United States

Atlanta, Georgia, United States

Worcester, Massachusetts, United States

Battle Creek, Michigan, United States

Dearborn, Michigan, United States

Grand Rapids, Michigan, United States

Reno, Nevada, United States

Oconomowoc, Wisconsin, United States

Sheboygan, Wisconsin, United States

West Allis, Wisconsin, United States

Greenville, North Carolina, United States

Naperville, Illinois, United States

Huntington, West Virginia, United States

Libertyville, Illinois, United States

Livonia, Michigan, United States

East Syracuse, New York, United States

Oshkosh, Wisconsin, United States

Charleston, South Carolina, United States

Albuquerque, New Mexico, United States

Mobile, Alabama, United States

Pensacola, Florida, United States

Boise, Idaho, United States

Royal Oak, Michigan, United States

Charleston, West Virginia, United States

Sherbrooke, Quebec, Canada

Saint Joseph, Michigan, United States

Park Ridge, Illinois, United States

San Antonio, Texas, United States

Elgin, Illinois, United States

Torrington, Connecticut, United States

Warrenville, Illinois, United States

Grafton, Wisconsin, United States

Greenville, South Carolina, United States

Greenville, South Carolina, United States

Atlanta, Georgia, United States

Chicago, Illinois, United States

Geneva, Illinois, United States

Boiling Springs, South Carolina, United States

Burlington, Wisconsin, United States

Germantown, Wisconsin, United States

Green Bay, Wisconsin, United States

Kenosha, Wisconsin, United States

Marinette, Wisconsin, United States

Milwaukee, Wisconsin, United States

Racine, Wisconsin, United States

Summit, Wisconsin, United States

Two Rivers, Wisconsin, United States

Wauwatosa, Wisconsin, United States

South Pasadena, California, United States

Saint Louis, Missouri, United States

Fresno, California, United States

Modesto, California, United States

Atlanta, Georgia, United States

Fruitland, Idaho, United States

Meridian, Idaho, United States

Nampa, Idaho, United States

Twin Falls, Idaho, United States

Farmington Hills, Michigan, United States

Oregon City, Oregon, United States

Nashville, Tennessee, United States

Lancaster, California, United States

Lubbock, Texas, United States

San Juan, , Puerto Rico

Saint Peters, Missouri, United States

Farmington Hills, Michigan, United States

Effingham, Illinois, United States

Mattoon, Illinois, United States

Yorkville, Illinois, United States

Louisville, Kentucky, United States

Brighton, Michigan, United States

Canton, Michigan, United States

Chelsea, Michigan, United States

Novi, Michigan, United States

Ypsilanti, Michigan, United States

Sturgeon Bay, Wisconsin, United States

Albuquerque, New Mexico, United States

New Haven, Connecticut, United States

Dublin, California, United States

Sacramento, California, United States

San Rafael, California, United States

Norton Shores, Michigan, United States

Creve Coeur, Missouri, United States

Saint Louis, Missouri, United States

Greenville, South Carolina, United States

Milwaukee, Wisconsin, United States

Elizabeth, New Jersey, United States

Mukwonago, Wisconsin, United States

Waukesha, Wisconsin, United States

Trumbull, Connecticut, United States

Atlanta, Georgia, United States

El Paso, Texas, United States

Plainfield, Illinois, United States

Derby, Connecticut, United States

Fairfield, Connecticut, United States

North Haven, Connecticut, United States

Waterbury, Connecticut, United States

Waterford, Connecticut, United States

Dekalb, Illinois, United States

Greenwich, Connecticut, United States

Jersey City, New Jersey, United States

Bellevue, Nebraska, United States

Omaha, Nebraska, United States

Lake Forest, Illinois, United States

Libertyville, Illinois, United States

Upland, California, United States

Saskatoon, Saskatchewan, Canada

Irvine, California, United States

Stamford, Connecticut, United States

Barrington, Illinois, United States

Crystal Lake, Illinois, United States

Kalamazoo, Michigan, United States

Cudahy, Wisconsin, United States

Goodyear, Arizona, United States

Glastonbury, Connecticut, United States

Westerly, Rhode Island, United States

East Lansing, Michigan, United States

Torrance, California, United States

Newport Beach, California, United States

Nampa, Idaho, United States

Long Beach, California, United States

Shiloh, Illinois, United States

Sheboygan, Wisconsin, United States

Mineola, New York, United States

Macon, Georgia, United States

Indianapolis, Indiana, United States

Lebanon, New Hampshire, United States

Wyoming, Michigan, United States

Grand Rapids, Michigan, United States

Muskegon, Michigan, United States

Ann Arbor, Michigan, United States

Webster, New York, United States

Danville, Illinois, United States

Guilford, Connecticut, United States

Orland Park, Illinois, United States

West Palm Beach, Florida, United States

Quebec, , Canada

Glenview, Illinois, United States

Grayslake, Illinois, United States

Reed City, Michigan, United States

Saint Joseph, Michigan, United States

O'fallon, Illinois, United States

Grand Rapids, Michigan, United States

Rockford, Illinois, United States

Madison, Wisconsin, United States

Grand Rapids, Michigan, United States

Huntington Beach, California, United States

Royal Oak, Michigan, United States

Irvine, California, United States

Dearborn, Michigan, United States

Farmington Hills, Michigan, United States

Troy, Michigan, United States

Royal Oak, Michigan, United States

Camillus, New York, United States

Atlanta, Georgia, United States

Madison, Wisconsin, United States

Ankeny, Iowa, United States

Clive, Iowa, United States

Des Moines, Iowa, United States

Des Moines, Iowa, United States

Corona, California, United States

Waukee, Iowa, United States

Patients applied

0 patients applied

Trial Officials

Kara M Kelly

Principal Investigator

Roswell Park Cancer Institute

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials